Ubiquitin, mAb Ubi-1
The monoclonal antibody Ubi-1 recognizes ubiquitin, both conjugated and unconjugated. Ubiquitin is a highly conserved globular 76 amino acid protein of about 8.5 kDa. It has an important role in the targeting of proteins for proteolytic degradation. Proteins to be degraded are covalently coupled to the C-terminus of ubiquitin by means of ubiquitin ligases. The ubiquitin itself is frequently also ubiquitinated, producing a polyubiquitin chain. The polyubiquitinated complex is then recognized by a complex of degradative enzymes which form the proteosome. Ubiquitin is also covalently attached to a variety of other pathological inclusions seen in human diseases which appear to be resistant to normal degradation. These inclusions include the neurofibrillary tangles of Alzheimer’s disease and progressive supranuclear palsy, Pick bodies of Pick’s disease, Lewy bodies of Parkinson’s disease, Mallory bodies of alcoholic liver disease, Rosenthal fibers of Alexander’s disease, and the inclusion bodies in inclusion myositis and oculopharyngeal muscular dystrophy. The ubiquitin molecule appears to be present in all eukaryotic cells and has an identical primary structure in all animals. Reactivity has been shown in human, bovine, chicken, Drosophilia and C. elegans. Ubiquitin is present in the nucleus, cytoplasm and on cell surface membranes. The monoclonal antibody Ubi-1 was raised against purified bovine ubiquitin conjugated with glutaraldehyde to keyhole limpet hemocyanin.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA